Skandinaviska Enskilda Banken AB publ Reduces Stake in Catalent, Inc. (NYSE:CTLT)

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Catalent, Inc. (NYSE:CTLT) by 78.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,495 shares of the company’s stock after selling 124,944 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Catalent were worth $1,940,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Capital World Investors lifted its position in Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares in the last quarter. Magnetar Financial LLC acquired a new position in Catalent during the 1st quarter valued at approximately $56,429,000. Cadian Capital Management LP boosted its holdings in shares of Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after acquiring an additional 759,600 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Catalent by 2,792.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after purchasing an additional 498,540 shares during the period. Finally, Beryl Capital Management LLC acquired a new stake in Catalent in the 1st quarter valued at approximately $23,756,000.

Catalent Price Performance

NYSE CTLT opened at $59.73 on Tuesday. The stock’s 50-day moving average is $59.52 and its two-hundred day moving average is $57.24. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77. The firm has a market cap of $10.81 billion, a P/E ratio of -9.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. On average, analysts anticipate that Catalent, Inc. will post 1.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CTLT has been the subject of a number of research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Barclays lifted their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Finally, StockNews.com assumed coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $58.08.

Insiders Place Their Bets

In other news, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the transaction, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is currently owned by company insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.